AbbVie(DE:4AB)
€259.70-3.10 (-1.18%)
DE:4AB
AbbVie stock forecast
€259.70
At close:-3.10 (-1.18%)
AbbVie (4AB) Stock Forecast & Price Target
28 Followers
4AB Analyst Ratings
Strong Buy
19Buy4Hold0Sell
Based on 23 analysts giving stock ratings to AbbVie in the past 3 months
4AB Stock 12 Month Forecast
Average Price Target
EUR 279.25▲(7.53% Upside)Based on 23 Wall Street analysts offering 12 month price targets for AbbVie in the last 3 months. The average price target is EUR 279.25 with a high forecast of EUR 310.27 and a low forecast of EUR 206.25. The average price target represents a 7.53% change from the last price of EUR 259.70.
Past 12 Months12 Month ForecastJan2026Oct2026
HighEUR 310.27
AverageEUR 279.25
LowEUR 206.25
Highest Price TargetHighestEUR 310.27Average Price TargetEUR 279.25Lowest Price TargetLowestEUR 206.25
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Trung Huynh | RBC Capital | EUR 295.92 | buy | 13.95%Upside | Reiterated | 11/05/26 | ||
| Ilya Zubkov | Freedom Capital Markets | EUR 255.57→EUR 282.47 | buy | 8.77%Upside | Reiterated | 11/04/26 | ||
| Asad Haider | Goldman Sachs | EUR 263.64→EUR 280.68 | hold | 8.08%Upside | Reiterated | 11/02/26 | ||
| Michael Yee | UBS | EUR 246.60→EUR 264.54 | hold | 1.86%Upside | Assigned | 11/02/26 | ||
| Terence Flynn | Morgan Stanley | EUR 277.99→EUR 310.27 | buy | 19.47%Upside | Assigned | 11/02/26 | ||
| Geoff Meacham | Citi | EUR 233.15→EUR 264.54 | hold | 1.86%Upside | Reiterated | 11/02/26 | ||
| Gary Nachman | Canaccord Genuity | EUR 260.05→EUR 303.10 | buy | 16.71%Upside | Reiterated | 11/02/26 | ||
| David Risinger | Leerink Partners | EUR 250.19→EUR 291.44 | buy | 12.22%Upside | Reiterated | 11/02/26 | ||
| Evan Seigerman | BMO Capital | EUR 304.89 | buy | 17.40%Upside | Reiterated | 11/02/26 | ||
| Vamil Divan | Guggenheim | EUR 258.26→EUR 288.75 | buy | 11.19%Upside | Reiterated | 11/01/26 | ||
| Carter Gould | Cantor Fitzgerald | EUR 260.05→EUR 291.44 | buy | 12.22%Upside | Reiterated | 11/01/26 | ||
| Jason Gerberry | Bank of America Securities | EUR 273.51→EUR 286.06 | buy | 10.15%Upside | Reiterated | 10/30/26 | ||
| Mohit Bansal | Wells Fargo | EUR 269.02→EUR 304.89 | buy | 17.40%Upside | Reiterated | 10/30/26 | ||
| Louise Chen | Scotiabank | EUR 286.96 | buy | 10.50%Upside | Reiterated | 10/29/26 | ||
| David Amsellem | Piper Sandler | EUR 271.71 | buy | 4.63%Upside | Reiterated | 10/26/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Trung HuynhRBC Capital | BuyReiteratedEUR 295.92 | 11/05/26 | 13.95%Upside | ||
| Ilya ZubkovFreedom Capital Markets | BuyReiteratedEUR 255.57→EUR 282.47 | 11/04/26 | 8.77%Upside | ||
| Asad HaiderGoldman Sachs | HoldReiteratedEUR 263.64→EUR 280.68 | 11/02/26 | 8.08%Upside | ||
| Michael YeeUBS | HoldAssignedEUR 246.60→EUR 264.54 | 11/02/26 | 1.86%Upside | ||
| Terence FlynnMorgan Stanley | BuyAssignedEUR 277.99→EUR 310.27 | 11/02/26 | 19.47%Upside | ||
| Geoff MeachamCiti | HoldReiteratedEUR 233.15→EUR 264.54 | 11/02/26 | 1.86%Upside | ||
| Gary NachmanCanaccord Genuity | BuyReiteratedEUR 260.05→EUR 303.10 | 11/02/26 | 16.71%Upside | ||
| David RisingerLeerink Partners | BuyReiteratedEUR 250.19→EUR 291.44 | 11/02/26 | 12.22%Upside | ||
| Evan SeigermanBMO Capital | BuyReiteratedEUR 304.89 | 11/02/26 | 17.40%Upside | ||
| Vamil DivanGuggenheim | BuyReiteratedEUR 258.26→EUR 288.75 | 11/01/26 | 11.19%Upside | ||
| Carter GouldCantor Fitzgerald | BuyReiteratedEUR 260.05→EUR 291.44 | 11/01/26 | 12.22%Upside | ||
| Jason GerberryBank of America Securities | BuyReiteratedEUR 273.51→EUR 286.06 | 10/30/26 | 10.15%Upside | ||
| Mohit BansalWells Fargo | BuyReiteratedEUR 269.02→EUR 304.89 | 10/30/26 | 17.40%Upside | ||
| Louise ChenScotiabank | BuyReiteratedEUR 286.96 | 10/29/26 | 10.50%Upside | ||
| David AmsellemPiper Sandler | BuyReiteratedEUR 271.71 | 10/26/26 | 4.63%Upside |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering AbbVie
3 Months
Success Rate12/15 ratings generated profit
80%
Average Return
+8.88%
Copying David Amsellem's trades and holding each position for 3 Months would result in 80.00% of your transactions generating a profit, with an average return of +8.88% per trade.
1 Year
Success Rate15/15 ratings generated profit
100%
Average Return
+28.09%
Copying David Amsellem's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +28.09% per trade.
2 Years
Success Rate32/32 ratings generated profit
100%
Average Return
+44.09%
Copying Mohit Bansal's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +44.09% per trade.
4AB Analyst Recommendation Trends
| Rating | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 |
| Buy | 48 | 51 | 50 | 60 | 56 |
| Hold | 10 | 9 | 6 | 8 | 11 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 58 | 60 | 56 | 68 | 67 |
In the current month, 4AB has received 56 Buy Ratings, 11 Hold Ratings, and 0 Sell Ratings. 4AB average Analyst price target in the past 3 months is 279.25.
4AB Financial Forecast
HighEUR 3.56
ConsensusEUR 3.46
LowEUR 3.42
4AB Earnings Forecast
Next quarter’s earnings estimate for 4AB is EUR 3.46 with a range of EUR 3.42 to EUR 3.56. The previous quarter’s EPS was EUR 3.39. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
HighEUR 16.4B
ConsensusEUR 16.3B
LowEUR 15.5B
4AB Sales Forecast
Next quarter’s sales forecast for 4AB is EUR 16.30B with a range of EUR 15.52B to EUR 16.42B. The previous quarter’s sales results were EUR 15.46B. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
4AB Stock Forecast FAQ
What is DE:4AB’s average 12-month price target, according to analysts?
Based on analyst ratings, AbbVie’s 12-month average price target is €279.25.
What is DE:4AB’s upside potential, based on the analysts’ average price target?
AbbVie has 7.53% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is AbbVie a Buy, Sell or Hold?
AbbVie has a consensus rating of Strong Buy, which is based on 19 buy ratings, 4 hold ratings and 0 sell ratings.
What is AbbVie’s share price target?
The average share price target for AbbVie is €279.25. This is based on 23 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €310.27, and the lowest forecast is €206.25. The average share price target represents a 7.53% increase from the current price of €259.7.
What do analysts say about AbbVie?
AbbVie’s analyst rating consensus is a Strong Buy. This is based on the ratings of 23 Wall Street analysts.
How can I buy shares of AbbVie?
To buy shares of DE:4AB, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
